Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities
Net loss	$ (3,803,000)	$ (1,555,000)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Stock option compensation expense	1,107,000	1,027,000
Common stock issued for services	333,000	265,000
Bad debt expense	37,000	9,000
PPP loan forgiveness	0	(97,000)
Amortization of debt discount	67,000	0
Amortization of right-of-use operating lease assets	55,000	48,000
Amortization of right-of-use finance lease asset	33,000	0
Operating lease liabilities	(50,000)	(39,000)
Finance lease liability	(43,000)	0
(Gain) loss on investment in South Korean joint venture	(9,000)	1,000
Depreciation expense	78,000	72,000
Changes in assets and liabilities:
Accounts receivable	(2,368,000)	499,000
Inventories	(114,000)	(23,000)
Prepaid expenses and other assets	33,000	(7,000)
Deposits	68,000	(36,000)
Contract liabilities	0	(218,000)
Net cash (used in) provided by operating activities	(3,948,000)	330,000
Cash flows from investing activities
Equipment purchases	0	(1,221,000)
Proceeds from note receivable	192,000	0
Net cash provided by (used in) investing activities	192,000	(1,221,000)
Cash flows from financing activities
Proceeds from sale of common stock, net of commissions	793,000	624,000
Proceeds from note payable	50,000	0
Proceeds from warrant exercise	0	216,000
Proceeds from option exercise	0	85,000
Repayment of debt obligations	(9,000)	(8,000)
Proceeds from Clyra Medical debt obligations	1,261,000	0
Net cash provided by financing activities	3,699,000	2,082,000
Net effect of foreign currency translation	(20,000)	35,000
Net change in cash	(77,000)	1,226,000
Cash and cash equivalents at beginning of period	3,548,000	3,539,000
Cash and cash equivalents at end of period	3,471,000	4,765,000
Supplemental disclosures of cash flow information
Interest	37,000	14,000
Income taxes	0	5,000
Short-term lease payments not included in lease liabilities	12,000	25,000
Non-cash investing and financing activities
Conversion of accounts receivable to a note receivable	3,764,000	0
Allocation of noncontrolling interest	504,000	(2,166,000)
Fair value of Clyra Medical warrants issued as debt discount	162,000	0
Clyra Medical dividend Series A Preferred stock	172,000	172,000
Conversion of BETI Common Stock to BioLargo Common Stock [Member]
Non-cash investing and financing activities
Conversion of BETI common stock to BioLargo common stock	0	50,000
Clyra Medical Technologies [Member]
Cash flows from financing activities
Proceeds from warrant exercise	1,309,000	0
BETI Common Stock [Member]
Cash flows from financing activities
Proceeds from sale of common stock	0	50,000
Clyra Medical Common Stock [Member]
Cash flows from financing activities
Proceeds from sale of common stock	295,000	1,115,000
Entities, Excluding Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	484,000	14,000
Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	$ 144,000	$ 370,000